Navigation Links
Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
Date:2/7/2008

Aprotinin plus ACE inhibitor associated with renal woes during off-pump surgery, U.K. study finds

THURSDAY, Feb. 7 (HealthDay News) -- While use of the clotting drug aprotinin (Trasylol) appears safe during on-pump cardiac surgeries, combining it with angiotensin-converting enzyme (ACE) inhibitors during off-pump cardiac surgery shows a significant risk of postoperative kidney dysfunction, British researchers say.

The study was prompted by previous research that noted an association between use of aprotinin -- which reduces the risk of bleeding during complicated surgeries -- and renal failure. Drug maker Bayer voluntarily suspended worldwide marketing of aprotinin after preliminary findings from a Canadian study (BART) suggested the drug increased the risk of death. That trial was halted in October 2007. Shortly after that, the U.S. Food and Drug Administration pulled the drug from the American market.

For this study, researchers analyzed the cases of 9,875 cardiac surgery patients. Most of the patients (5,434) had on-pump cardiac surgery, which means their hearts were stopped and they were hooked up to a heart-bypass machine during surgery. The other patients had off-pump cardiac surgery -- doctors operated on their beating hearts.

Among patients who had on-pump surgery, there was no significant association between aprotinin and postoperative renal dysfunction, irrespective of ACE inhibitor use. However, aprotinin was associated with a more than twofold increased risk of renal dysfunction among the 848 patients who had off-pump cardiac surgery and received both aprotinin and ACE inhibitors.

"We recommend that it might be beneficial for patients to discontinue any use of an ACE inhibitor before elective off-pump surgery, particularly patients with a history of renal impairment," wrote Dr. Ronelle Moulton and Kai Zacharowski, from the department of anesthesia, Bristol Royal Infirmary, United Bristol Healthcare Trust.

Their study was published in this week's issue of The Lancet.

A complete analysis of the BART findings will not be known for some time, Dr. Derek Hausenloy, of The Hatter Cardiovascular Institute, University College London Hospital and Medical School, and colleagues wrote in an accompanying comment.

"While waiting for that analysis, the use of aprotinin in the U.S. and in some European countries has been necessarily restricted, with the consequence that some high-risk patients having cardiac surgery might not receive optimum therapy," Hausenloy and colleagues noted.

More information

The U.S. National Heart, Lung, and Blood Institute has more about heart surgery.



-- Robert Preidt



SOURCE: The Lancet, news release, Feb. 7, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Combo Therapy Shows Promise in Treating Brain Tumors
2. Combo Treatment Best for Elderly Lymphoma Patients
3. Combo Therapy Cuts Prostate Cancer Death Rates
4. Drug Combo Halves Death Risk for Severe COPD Patients
5. Aspirin, Hormone Therapy Combo Can Shorten Lives of Prostate Cancer Patients
6. New Combo Treatment Extends Kidney Cancer Survival
7. Drug Combo With Antibiotic May Slow MS Progression
8. Combo PET/CT Scan Helps Spot Breast Cancers Spread
9. Drug Combos Effective Against Rheumatoid Arthritis
10. Drug Combo Boosts Multiple Myeloma Survival
11. CPR, Defibrillator Combo Boosts Cardiac Incident Survival
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Drug Combo Tied to Kidney Risk With Some Cardiac Surgeries
(Date:6/26/2016)... ... June 26, 2016 , ... On June 10-11, 2016, A Forever ... Cereal Festival and World’s Longest Breakfast Table in Battle Creek, MI, where the rehabilitation ... as home to some of the world’s leading providers of cereal and other breakfast ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from ... at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center ... care topics including advance care planning, healthcare costs and patient and family engagement. ...
(Date:6/25/2016)... CA (PRWEB) , ... June 25, 2016 , ... As ... with Magna Cum Laude and his M.D from the David Geffen School of Medicine ... and returned to Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive ...
(Date:6/24/2016)... Michigan (PRWEB) , ... June 24, 2016 , ... Those ... deal with these feelings, many turn to unhealthy avenues, such as drug or alcohol ... of Marne, Michigan, has released tools for healthy coping following a traumatic event. , ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with all ... brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a revolutionary ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 24, 2016  Collagen Matrix, Inc., ("Collagen Matrix") ... manufacturing of collagen and mineral based medical devices ... Bill Messer has joined the company ... leverage the growing portfolio of oral surgery, neurosurgery, ... Bill joins the Collagen Matrix executive team as ...
(Date:6/24/2016)... The Academy of Managed Care Pharmacy (AMCP) ... would allow biopharmaceutical companies to more easily share health ... and coverage decisions, a move that addresses the growing ... The recommendations address restrictions in the sharing of ... label, a prohibition that hinders decision makers from accessing ...
(Date:6/24/2016)... 24, 2016   Pulmatrix, Inc ., (NASDAQ: ... inhaled drugs, announced today that it was added to ... its comprehensive set of U.S. and global equity ... an important milestone for Pulmatrix," said Chief Executive Officer ... of our progress in developing drugs for crucial unmet ...
Breaking Medicine Technology: